NewsBenzingaRevelation Biosciences Plans Accelerate Development Of Its Therapeutic Candidate Gemini; New Streamlined Phase 2a Study In Acute Kidney Injury To Deliver Topline Data In 2027 At Nearly 90% Lower Costs Revelation Biosciences Plans Accelerate Development Of Its Therapeutic Candidate Gemini; New Streamlined Phase 2a Study In Acute Kidney Injury To Deliver Topline Data In 2027 At Nearly 90% Lower Costs Benzinga 2026.11.16 14:13 (GMT+0) Open on Benzinga Other news A whale accumulates 238,400 LINK from Binance in two days, worth about $2.2 million Huobi HTX to Open Spot Trading for SOXS, KORU and SNXX on November 17 Duan Yongping Trims Nvidia and Apple in Q3, Exits Alibaba and CRCL, Opens New SpaceX Stake Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds US Says Justice Leads Megaspeed AI-Chip Investigation Soluna Holdings, Inc. (SLNH) Q3 2026 Earnings Call Transcript
Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds